4,942 reports of this reaction
4.5% of all UPADACITINIB reports
#1 most reported adverse reaction
PAIN is the #1 most commonly reported adverse reaction for UPADACITINIB, manufactured by AbbVie Inc.. There are 4,942 FDA adverse event reports linking UPADACITINIB to PAIN. This represents approximately 4.5% of all 110,317 adverse event reports for this drug.
UPADACITINIB has an overall safety score of 85 out of 100. Patients taking UPADACITINIB who experience pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PAIN is moderately reported among UPADACITINIB users, representing a notable but not dominant share of adverse events.
In addition to pain, the following adverse reactions have been reported for UPADACITINIB:
The following drugs have also been linked to pain in FDA adverse event reports:
PAIN has been reported as an adverse event in 4,942 FDA reports for UPADACITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PAIN accounts for approximately 4.5% of all adverse event reports for UPADACITINIB, making it one of the most commonly reported side effect.
If you experience pain while taking UPADACITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.